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Non-adherence to stroke prevention medications is a risk factor for first-ever and recurrent
stroke. As of yet, there are no guidelines for processes to recognize and address med-
ication non-adherence in stroke patients. We developed a new model of post-discharge
prevention care that measures and addresses medication-taking (transition coaching for
stroke or TRACS). TRACS includes personalized education about risk factors and medica-
tions prior to discharge, follow-up telephone calls, and appointments with a stroke nurse
practitioner (NP). The stroke NP asks about medication use (persistence) and whether
doses are missed (adherence), and helps to solve problems with access to medications
or side effects. In an analysis of 142 patients enrolled in TRACS from October 2012 to
February 2014, medication persistence (use of medications from discharge to the time
of measurement) was about 80%. Medication persistence at NP visit was higher in those
patients with a first-ever stroke (78.9%) vs. those with recurrent stroke (60.7%; p=0.045).
Concerted efforts with 2-day RN follow-up calls and earlier NP appointments to improve
medication-taking behaviors are underway.
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INTRODUCTION
There are approximately 795,000 new strokes per year in the US,
23% of which are recurrent (1). The risk factors for stroke are well-
recognized, and risk-stratification according to the presence of
diabetes, hyperlipidemia, atrial fibrillation, current tobacco smok-
ing, and hypertension occurs primarily during the hospitalization
for acute stroke. Medications are then prescribed to modify these
risk factors with the intent of reducing the risk of recurrent stroke.
Evidenced-based guidelines focused on secondary prevention of
stroke provide recommendations for treatments for each of these
risk factors (2).
The processes of improving risk reduction during the acute hos-
pital stay have been incorporated into quality improvement pro-
grams such as American Heart Association/American Stroke Asso-
ciation’s get-with-the-guidelines – stroke and Paul Coverdell Acute
Stroke Registries. These programs provide feedback on processes
of care that are now publicly reported as core performance mea-
sures, such as measurement of a lipid profile and treatment with
a statin, anticoagulation for atrial fibrillation, and antithrombotic
therapy for prevention early in the hospital course (hospitalcom-
pare.gov). These programs, however, are not specifically designed
to maintain stroke prevention efforts after discharge.
Prescription of evidenced-based stroke prevention medications
is only the first step. If patients are not willing or able to take
these medications, then the action was futile. The final frontier for
improving the quality of stroke secondary prevention, therefore,
is finding ways to improve medication adherence (3). A recent
Cochrane Systematic Review of randomized controlled trials test-
ing educational and behavioral interventions to improve stroke
prevention (including adherence to prescribed medications) was
published. Unfortunately, the authors reported that none of these
interventions led to significant improvement in medication adher-
ence or recurrent cardiovascular events (4). More work is needed to
identify effective strategies to improve adherence and thus enhance
the effectiveness of secondary prevention.
MEDICATION NON-ADHERENCE: AN UNDER-RECOGNIZED RISK
FACTOR FOR STROKE
Non-adherence to medications in patients at risk for stroke is an
important risk factor in and of itself. For example, the heart and
soul study showed that in patients with coronary artery disease, if
patients only took 75% or less of their medications as prescribed,
the risk for stroke was fourfold higher than patients who were
100% adherent (5). Similarly, a post hoc analysis of the vitamins in
stroke prevention (VISP) study investigated the impact of general
non-adherence to study medication, whether it was the active vita-
min preparation or placebo and the impact on the outcome. Com-
pared to<65% adherence, pill adherence levels of≥90 to<99 and
≥99% were associated with a 44% (p= 0.02) and 54% (p= 0.001),
respectively, lower occurrence of the combined outcome of stroke,
myocardial infarction, or death at 18 months (6). A study of
Tennessee’s Medicaid program from 1994 to 2000 showed that
antihypertensive medication adherence by one pill per week for a
once-a-day regimen reduced the risk of stroke by 8–9% and death
by 7% (7). A separate analysis of stroke patients in a Medicaid pro-
gram showed that stroke recurrence was 57% less likely if patients
consistently took medications over time (i.e., persistent), even after
adjusting for confounders (8). Unfortunately, stroke patients are a
high-risk group just by virtue of having suffered one. For example,
in the international reduction of atherothrombosis for continued
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health (REACH) registry, experiencing a non-fatal stroke was a
predictor of non-adherence with cardiovascular prevention med-
ications (9). Therefore, overwhelmingly the evidence points to
adherence as a critically important factor in stroke prevention,
and yet screening for and recognizing non-adherence is not yet an
established part of any process measure of quality for stroke.
WHAT IS KNOWN ABOUT MEDICATION ADHERENCE IN STROKE?
Medication-taking behavior can be categorized as persistence
or adherence. Medication persistence is defined as the duration
of therapy, whereas adherence is the extent to which patients
take their medications as prescribed (i.e., not missing doses).
The adherence evaluation after ischemic stroke – longitudinal
(AVAIL) registry was designed a priori to account for the patient,
provider, and system factors that may impact medication persis-
tence/adherence in stroke patients (10). AVAIL used self-reported
3-month secondary medication regimen persistence (comparing
medication lists at discharge and at 3 and 12 months after stroke) as
the primary outcome. The primary findings were that medication
persistence at 3 months was 75%. Some of the factors associated
with persistence were decreasing number of medications, history
of hypertension, diabetes, and hyperlipidemia, less severe stroke
disability, higher quality of life, having insurance, working sta-
tus, and understanding why medications are prescribed and how
to refill them (11). At 1 year, non-persistence (discontinuation
of a medication for any reason, including provider recommen-
dations) and non-adherence (discontinuation for reasons other
than provider recommendations) were analyzed separately. One-
year persistence (65.6%) and adherence (86.6%) differed, based
on the assumption that provider-recommended discontinuation
accounted for most, but not all, of the non-persistence. Some
factors associated with persistence and/or adherence included
decreasing number of medications, adequate income, lesser dis-
ability from stroke, having an appointment with a primary care
physician (PCP), using a pillbox, having insurance, receiving
medication instructions at discharge, marital status, and being
discharged to home (12).
The results from other studies of medication-taking among
stroke patients have reported considerable variability. Analysis
of a Medicaid managed care database from Maryland reported
the persistence in stroke patients was about 80% after maximum
follow-up of 2 years (8). In Nova Scotia, Canada, self-reported
medication persistence at 6 months ranged from 83.3% for anti-
coagulants to 97.1% for anti-hyperglycemic drugs. At 12 months,
the ranges were nearly identical for the various categories of
medications (13).
In contrast, an analysis of over 21,000 stroke survivors in
the Sweden showed a steady decline in medication persistence
from discharge to 2-year follow-up (14). After 2 years, medication
persistence ranged from 74% for antihypertensive drugs to only
45% for warfarin. The factors associated with non-persistence in
this cohort were advanced age, comorbidity, good self-perceived
health, absence of low mood, acute treatment in a stroke unit,
and institutional living at follow-up (14). These studies illustrate
the variability in persistence across different settings, which could
relate to heterogeneity in healthcare systems, cultural factors, and
methods to measure adherence.
STRATEGIES TO IMPROVE ADHERENCE TO STROKE PREVENTION
MEDICATIONS
The preventing recurrence of thromboembolic events through
coordinated treatment (PROTECT) program was a quality
improvement program designed to increase adherence with med-
ications and behavioral changes after stroke and acute coronary
artery syndrome (15). Patients admitted to a single center were
discharged with materials related to appointments, and at 2–
4 weeks, a nurse contacted patients by telephone to reinforce
medication/behavior regimens. In the 130 patients followed up at
3 months, adherence to antithrombotics was 100%, statins 99%,
angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers 92%, thiazides 80%, diet 78%, exercise 70%, and smok-
ing cessation 83% (15). At 1 year, persistence in 128 patients was
maintained at a similar rate, demonstrating that medications can
be successfully improved and maintained through early initiation
and encouragement after discharge (16). This study, however, had
no control group.
The AVAIL results showed that specific patient-related factors,
such as knowledge of why medications are taken and how to refill
them were associated with medication persistence at 3 months.
Therefore, we designed a medication coaching intervention that
would focus on these factors as well as providing non-medication
help for patients or families that needed it (17). In a two-arm study
of stroke patients who had a change of at least 2 prevention med-
ications between admission and discharge, 20 were assigned to the
intervention, and 10 to usual care. The medication coach enrolled
patients in the hospital prior to discharge and provided educa-
tional materials. She then contacted participants at about 2 weeks
after discharge to review medications and to triage open-ended
questions about medications to a pharmacist or questions about
stroke to a stroke nurse. The information was then compiled and
given to the participant by telephone. Overall, the program was
well-received by those who received the intervention, and we noted
a trend toward improved appointment-keeping with primary care
in those who received the coaching. Not surprisingly, the sam-
ple was too small to assess differences in medication persistence
(17). The theme of the questions asked by patients and caregivers
focused on how to prevent another stroke, and how to take medica-
tions to avoid interactions. We learned that although many of the
questions and concerns about medications and stroke were simi-
lar, there were other system failures, such as difficulties obtaining
appointments, and social issues, such as lack of transportation
to appointments for providers and physical/occupational/speech
therapy. Medication adherence is obviously critically important,
but as we learned in our coaching intervention, it was actually the
tip of the iceberg. An effective prevention model would require
recognition of medication non-adherence and also readiness by
the team to provide individualized assistance and education during
the transition from hospital to home.
A NEWMODEL OF STROKE PREVENTION
TRACS PROGRAM DEVELOPMENT
The medication coaching pilot study informed the development
of the transitional coaching for stroke (TRACS) program, a
hospital-supported quality improvement program to reduce
30-day readmissions, maximize stroke prevention, and improve
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outcomes. The TRACS program provides one-on-one transition
coaching to patients admitted with an ischemic or hemorrhagic
stroke or TIA. The TRACS coach meets individually with patients
prior to discharge and provides a take-home packet with a person-
alized review of the patient’s risk factors, medication information,
instructions for stroke awareness, action with new symptoms, and
post-hospital follow-up care. These materials are given in large
font for a 7–8th grade reading level with a one page summary.
The coach explains new medications that have been added to
the patient’s regimen, behavioral changes that are necessary for
a successful transition and also answers any questions the patient
may have. Also, during transition coaching, the TRACS Program
Baseline Information Survey is administered, which collects infor-
mation regarding the health status, health literacy, depression,
insurance status, adequacy of income, and premorbid status.
After discharge, the TRACS coach (initially an educator, now an
RN) calls the patient within 2 weeks to assess medications, any new
problems after arriving home, and confirm appointments with the
patient or caregiver if patient is unable or unavailable to speak to
the coach. The next contact is in the stroke nurse practitioner
(NP) follow-up clinic between 2 and 4 weeks, where a standard-
ized assessment is performed. This includes screening for new
stroke symptoms, depression, and fall risk, assessing progress with
rehabilitation, providing referrals to home health if needed, con-
firming access to primary care, and discussion of diagnostic test
results from the stroke hospitalization. Importantly, self-reported
medication use and reconciliation is obtained at this visit, with
follow-up questions related to why a medication is not taken and
why, as well as steps to help with access to cheaper alternatives if
cost is an issue, or to address side effects by adjusting medications
or doses. Communication and coordination with the other health
care providers is also a major responsibility of the stroke NPs. For
patients with severe stroke deficits, information about medication
use is obtained from the caregiver.
The next telephone contact is at 3 months for ascertainment
of outcomes including the modified Rankin scale (mRS) (18),
Stroke Impact Scale (functional status with the SIS-16 and social
domain) (19, 20) primary care visits, change in insurance sta-
tus, recurrent stroke, or TIA, quality of life (EuroQOL-5-D) (21),
Emergency Department visits or hospital readmissions (diagno-
sis), cigarette smoking, working status, living status, household
income adequacy. A major portion of the 3-month outcome inter-
view focuses on a comparison of medications between the stroke
discharge and the stroke follow-up clinic, whichever occurred
last, in order to assess persistence, as well as reasons for dis-
continuation. Efforts in TRACS have focused on enrollment and
early follow-up. With limited personnel to perform 3-month
calls, medication use (persistence) was obtained by review of the
Wake Forest Baptist Medical Center (WFBMC) electronic health
records (EHR).
TRACS PERSONNEL
The TRACS team includes the TRACS coach and a stroke NP,
which allowed access to earlier stroke clinic follow-up than was
available with full resident and faculty clinics. Two years after the
initiation of the program, we hired a second stroke NP, which
then provided the opportunity for continuity of care from the
inpatient to the outpatient setting. The stroke NPs, TRACS coach,
and TRACS director all worked to develop a pathway for follow-up
calls and the timing for clinic visits. The identification of high-risk
profiles was based on an analysis of our 30-day readmission case–
control study showing that patients with prior hospitalizations
before the stroke are at the highest risk for readmission within
30 days (22). The stroke NPs developed the standardized follow-up
clinic assessment using a template in the EHR.
PROGRAM EVALUATION
By developing a database for entering data about medical his-
tory, health literacy, and availability of resources for participants,
we created a system that could be queried to evaluate quality
improvement efforts. We evaluated patients admitted to WFBMC
and discharged home between October 2012 and February 2014.
Patients were eligible for TRACS, if they were age 18 years or older
and hospitalization for a primary diagnosis of acute ischemic or
hemorrhagic stroke, or TIA. Patients who have been discharged to
a skilled nursing facility or outside inpatient rehabilitation facil-
ity were excluded from the analysis, but are still seen in the NP
follow-up clinic. Patients were contacted by the TRACS coach or
the stroke NPs according to the schedule above using telephone
follow-up or the NP follow-up clinic notes to ascertain stroke
prevention medication persistence.
Subjects prescribed an individual medication at discharge, but
who were not taking that medication at follow-up (clinic or phone
interview), were defined as“non-persistent.”Data collection forms
were programed for online data entry of baseline variables using
research electronic data capture (REDcap). The study protocol for
this analysis was approved by the Wake Forest School of Medicine
Institutional Review Board. The coach obtained verbal consent
during the enrollment process in the hospital.
EARLY PROGRAM RESULTS
Of the 171 patients enrolled, 15 patients (8.8%) were discharged
to a skilled nursing facility or outside inpatient rehabilitation facil-
ity, and 14 patients (8.2%) were lost to follow-up. A total of 142
patients were included in this analysis. Table 1 shows the base-
line characteristics of the analysis cohort. The mean age was 63.6
(range 26–100) years and 52.8% were women, and the proportions
with risk factors are shown in Table 1.
The overall medication regimen persistence (all medications
the same from discharge to follow-up) was 80.3%. The highest
persistence was with antithrombotic therapy (96.7%), followed by
diabetes medications (95.8%), lipid-lowering (86.7%), and antihy-
pertensive drugs (86.3%). Of the classes of antihypertensive drugs,
the lowest persistence was with calcium channel blockers (78.1%),
with 9.4% discontinued by the provider and the other 9.4% dis-
continued by the patient. The factors associated with persistence
are shown in Table 2. Persistence was higher in those patients with
a first-ever stroke (78.9%) vs. those with recurrent stroke (60.7%;
p= 0.045), whereas none of the other factors were associated with
persistence.
Multivariate logistic regression modeling revealed prior
stroke/TIA was negatively associated with persistence (OR 0.21,
95% CI 0.06–0.72; p= 0.013) after adjustment for age, sex, race,
education, insurance, and office visits after discharge. There was
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Table 1 | Baseline characteristics ofTRACS patients.
Total (n=142) IS (n=108) HS (n=13) TIA (n=21) p-value
Demographics
Age, years 63.6 (13.13) 62.8 (13.43) 62.1 (8.98) 68.8 (12.96) 0.146
Female 75 (52.8) 55 (50.9) 7 (53.8) 13 (61.9) 0.652
Medical history
Hypertension 127 (89.4) 96 (88.9) 12 (92.3) 19 (90.5) 0.918
Diabetes mellitus 51 (35.9) 37 (34.3) 5 (38.5) 9 (42.9) 0.739
Hypercholesterolemia 76 (53.5) 57 (52.8) 5 (38.5) 14 (66.7) 0.263
Coronary artery disease 35 (24.6) 29 (26.9) 2 (15.4) 4 (19.0) 0.539
Prior stroke/TIA 35 (24.6) 25 (23.1) 2 (15.4) 8 (38.1) 0.250
Congestive heart failure 18 (12.7) 12 (11.1) 3 (23.1) 3 (14.3) 0.459
Smoking 40 (28.2) 36 (33.3) 3 (23.1) 1 (4.8) 0.026
Alcohol abuse 15 (10.6) 12 (11.1) 1 (7.7) 2 (9.5) 0.918
Depression 18 (12.7) 16 (14.8) 0 (0) 2 (9.5) 0.283
Prior hospitalization 27 (19.0) 17 (15.7) 1 (7.7) 9 (42.9) 0.008
Clinical presentation
SBP (mmHg) 158.1 (27.03) 156.2 (25.61) 181.9 (39.78) 153.0 (16.70) 0.003
DBP (mmHg) 85.5 (18.43) 85.1 (16.29) 101.1 (30.08) 77.9 (14.61) 0.001
HbA1c (%) 6.7 (2.07) 6.8 (2.16) 5.9 (1.29) 6.6 (1.68) 0.655
Total cholesterol (mg/dL) 181.4 (46.08) 182.4 (43.62) 176.1 (44.77) 177.9 (61.06) 0.881
LDL-cholesterol (mg/dL) 109.8 (35.88) 111.9 (34.34) 102.3 (48.65) 100.2 (39.78) 0.397
HDL-cholesterol (mg/dL) 40.0 (12.47) 40.2 (11.97) 34.6 (5.76) 47.3 (15.03) 0.024
Triglyceride (mg/dL) 156.0 (119.6) 155.3 (108.35) 212.3 (147.08) 134.9 (162.77) 0.314
Neurological scale score, median (range)
Baseline NIHSS score 2.0 (0–32) 3.0 (0–32) 6.0 (0–27) 0.0 (0–9) 0.004
mRS at discharge 3.0 (0–5) 3.0 (0–5) 3.0 (1–4) 0.0 (0–0) 0.019
IS, ischemic stroke; HS, hemorrhagic stroke; TIA, transient ischemic attack; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein;
HDL, high-density lipoprotein; NIHSS, National Institutes of Health stroke scale; mRS, modified Rankin score. Bold text used to show variables with significant
p values.
Data are means (SD) or numbers (%).
also a trend toward prior hospitalization (before the index stroke)
and persistence (OR 4.73, 95% CI 0.99–22.50; p= 0.051).
DISCUSSION
The Institute of Medicine recommends integrated approach to
evidence-based prevention that also promotes patient access to
this care (23). We believe TRACS is an example of a model of
stroke prevention and transitional care that meets the Institute
of Medicine recommendation because of (1) appropriate initia-
tion of guideline-recommended prevention medications prior to
discharge; (2) enhanced literacy-appropriate education provided
at discharge with close telephone and clinic follow-up; (3) assess-
ment of medication adherence/persistence; and (4) a triage system
to provide community referrals for those patients who have prob-
lems with access to medications, regardless of insurance status. It
may be difficult to ask patients if they are having financial dif-
ficulties, but asking about medication-taking and access to those
medications opens a discussion with patients about their specific
challenges. If medication non-persistence is not recognized, these
patients are at even higher risk for recurrent stroke.
We also showed that analysis of the hospital and outpatient
EHR, and coach-acquired data can lead to identification of a
subgroup of patients at highest risk for non-persistence – those
who have already had a stroke prior to enrollment in TRACS.
This was independently associated with non-persistence, even
after adjustment for relevant sociodemographic factors. It is pos-
sible that non-persistence had been a chronic problem in these
patients with recurrent stroke, but perhaps had not been ade-
quately addressed with follow-up after the initial stroke or TIA.
The other possibility is that the patients with multiple strokes
have risk factors that are the most difficult to control, although
we did not find specific risk factors that were associated with non-
persistence in our data. For those who are hospitalized prior to
a stroke, perhaps this is an interaction that could improve per-
sistence through understanding the patient’s current medication-
taking behavior and adjusting medications accordingly. TRACS
will be the ideal platform to test new interventions for medication
adherence comparing outcomes in those who have a history of a
prior stroke vs. those with first-ever stroke.
Patients’beliefs about medications can have a significant impact
on adherence to stroke prevention medications. In Sweden, investi-
gators reported that in nearly 600 stroke survivors, non-adherent
participants scored lower on positive beliefs about medications
(necessity and benefit) and higher on negative beliefs (concern
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Age (years) 63.4 (12.95) 64.29 (14.05) 0.756
Female 59 (51.8) 16 (57.1) 0.609
Race
White 67 (76.1) 21 (23.9) 0.087
African American 23 (79.3) 6 (20.7)
Not reported 24 (96.0) 1 (4.0)
Education level
≥college 19 (16.7) 7 (25.0) 0.250
Work status
Working 32 (28.1) 4 (14.3) 0.249
Retired 35 (30.7) 13 (46.4)
Disabled 10 (8.8) 7 (25.0)
Not reported 37 (32.4) 4 (14.3)
Medical history
Hypertension 102 (89.5) 25 (89.3) 0.977
Diabetes mellitus 42 (36.8) 9 (32.1) 0.642
Hypercholesterolemia 60 (52.6) 16 (57.1) 0.668
Coronary artery disease 29 (25.4) 6 (21.4) 0.659
Prior stroke/TIA 23 (21.1) 11 (39.3) 0.045
System factors
Have insurance or help to
pay for meds
94 (82.5) 22 (78.6) 0.577
Length of admission (days) 3.2 (3.53) 3.7 (2.87) 0.509
Prior hospitalization 24 (21.1) 3 (14.3) 0.212
One or more office visits
after discharge
93 (81.6) 22 (78.6) 0.716
Bold text used to show variables with significant p values.
about harm) and they believed their current treatment to be
less useful (24). A synthesis of qualitative studies of medication
non-adherence concluded that the main theme was that patients
do not take their medications because of a reluctance to take
medicines in general, and prefer to take as little as possible (25).
Therefore, providers may need to find more effective ways of
acknowledging concerns patients have about medications and also
highlighting the necessity and benefit of reducing future stroke
risk. With the evidence about patient beliefs and concerns, and
the assumption that addressing these could lead to improved
prevention, researchers in the United Kingdom have designed
a pharmacist-led home-based clinical medication review inter-
vention that is currently under investigation in a randomized
controlled trial (26).
In summary, we believe that a comprehensive model of stroke
prevention should include recognition of non-adherence, and
understanding of the factors associated with this phenomenon.
The TRACS program is designed with medication-taking behav-
ior at the forefront, and will provide a platform for both quality
improvement efforts and design of new interventions to improve
adherence. With multiple clinical trials of organizational and
behavioral interventions currently underway, additional strategies
can be incorporated into the TRACS model to enhance adherence
and prevention of recurrent stroke even further.
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